GCA
IART icon

Gideon Capital Advisors’s Integra LifeSciences IART Stock Holding History

Gideon Capital Advisors’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,442
Closed -$471K – 436
2018
Q4 		$471K Buy
+10,442
New +$573K 0.19% 167
2018
Q1 		– Sell
-6,213
Closed -$297K – 400
2017
Q4 		$297K Buy
+6,213
New +$304K 0.26% 167

Other funds holding IART

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gideon Capital Advisors's IART Position: Q1 2019 in Review

Gideon Capital Advisors sold out of Integra LifeSciences (IART) in Q1 2019, closing a stake of 10,442 shares — an estimated $471K sold.

Gideon Capital Advisors first reported a position in IART in Q4 2017 and held it in 2 quarters. The position peaked at $471K in Q4 2018. 259 funds tracked by Wall St. Rank hold IART as of Q1 2019.

  • Gideon Capital Advisors reported no remaining Integra LifeSciences position as of Q1 2019 after selling out during the quarter.
  • Gideon Capital Advisors sold 10,442 Integra LifeSciences shares in Q1 2019, an estimated $471K.
  • Gideon Capital Advisors first reported a position in Integra LifeSciences in Q4 2017 and held it in 2 quarters.
  • Gideon Capital Advisors's Integra LifeSciences position peaked at $471K in Q4 2018.
  • 259 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2019.

Based on Gideon Capital Advisors's 13F filing for Q1 2019, filed 14 May 2019.